Skip to main content

Table 3 Comparison between four papilla types

From: Duodenal major papilla morphology can affect biliary cannulation and complications during ERCP, an observational study

Papilla Type

1 (n = 118)

2 (n = 25)

3 (n = 63)

4 (n = 80)

p value

Age

63 (50.5–74)

65 (58–78)

68 (55–77)

67 (57.25–75)

0.213

Gender-Male

66 (55.93%)

11 (44.00%)

31 (49.21%)

42 (52.50%)

0.670

Indication

    

0.589

 Stone

87 (73.73%)

16 (64.00%)

49 (77.78%)

57 (71.25%)

 

 Cancer

21 (17.80%)

4 (16.00%)

7 (11.11%)

15 (18.75%)

 

 Other

10 (8.47%)

5 (20.00%)

7 (11.11%)

8 (10.00%)

 

Diabetes

27 (22.88%)

6 (24.00%)

21 (33.33%)

22 (27.50%)

0.490

Hypertension

43 (36.44%)

11 (44.00%)

26 (41.27%)

50 (62.50%)

0.003**

CVA

8 (6.78%)

2 (8.00%)

3 (4.76%)

6 (7.50%)

0.912

CRI

13 (11.02%)

2 (8.00%)

6 (9.52%)

7 (8.75%)

0.941

COPD

3 (2.54%)

0 (0.00%)

5 (7.94%)

1 (1.25%)

0.084

CAD

8 (6.78%)

2 (8.00%)

3 (4.76%)

5 (6.25%)

0.936

Cirrhosis

6 (5.08%)

2 (8.00%)

3 (4.76%)

3 (3.75%)

0.860

Pre-cut

8 (6.78%)

5 (20.00%)

10 (15.87%)

8 (10.00%)

0.117

Fail cannulation

2 (1.69%)

3 (12.00%)

7 (11.11%)

5 (6.25%)

0.037*

Pancreatic wire passage > 2

19 (16.10%)

8 (32.00%)

15 (23.81%)

22 (27.50%)

0.152

Pancreatic wire passage time

0 (0–1)

0 (0–1)

1 (0–2)

1 (0–3)

0.036*

Cannulation time

    

0.001**

 0–5 min

67 (56.78%)

8 (32.00%)

19 (30.16%)

29 (36.25%)

 

 5–10 min

31 (26.27%)

4 (16.00%)

21 (33.33%)

23 (28.75%)

 

 > =10 min

20 (16.95%)

13 (52.00%)

23 (36.51%)

28 (35.00%)

 

PAD Type

    

0.128

 0

65 (55.08%)

13 (52.00%)

42 (66.67%)

46 (57.50%)

 

 2

12 (10.17%)

7 (28.00%)

5 (7.94%)

10 (12.50%)

 

 3

41 (34.75%)

5 (20.00%)

16 (25.40%)

24 (30.00%)

 

Biopsy

14 (11.86%)

2 (8.00%)

8 (12.70%)

9 (11.25%)

0.938

Sphincterotomy

99 (83.90%)

22 (88.00%)

56 (88.89%)

72 (90.00%)

0.600

ERBD

39 (33.05%)

9 (36.00%)

15 (23.81%)

23 (28.75%)

0.540

ERPD

6 (5.08%)

2 (8.00%)

5 (7.94%)

5 (6.25%)

0.872

Stone extraction

75 (63.56%)

14 (56.00%)

41 (65.08%)

49 (61.25%)

0.864

Lithotripsy

2 (1.69%)

1 (4.00%)

2 (3.17%)

2 (2.50%)

0.880

EPBD

2 (1.69%)

3 (12.00%)

0 (0.00%)

1 (1.25%)

0.003**

Platelet

230 (169.75–297.75)

201 (155.5–310)

197 (146–276)

211 (152.5–281.75)

0.426

PT

10 (10–11)

10 (9.8–10.7)

10 (10–11.1)

10 (10–10.9)

0.502

APTT

28 (26.2–29.93)

27 (25.63–29.85)

28 (26.4–30.35)

28 (26.5–29.55)

0.961

AST

116 (47–227)

53 (22.5–150.25)

105 (46.75–205)

104 (42.5–238)

0.205

ALT

140 (48–312.5)

50 (21.5–125.5)

125 (55–265)

114 (44.5–309.75)

0.022*

Bilirubin

3 (1.38–6.13)

4 (0.45–5.1)

4 (1.5–6.1)

3 (1–5.08)

0.503

Creatinine

1 (0.67–0.97)

1 (0.56–1.27)

1 (0.66–1.06)

1 (0.68–1.02)

0.970

Complications

 Perforation

1 (0.85%)

1 (4.00%)

0 (0.00%)

0 (0.00%)

0.174

 Pancreatitis

8 (6.78%)

5 (20.00%)

1 (1.59%)

5 (6.25%)

0.020*

 Bleeding

6 (5.08%)

2 (8.00%)

1 (1.59%)

3 (3.75%)

0.525

 Cholangitis

3 (2.54%)

0 (0.00%)

0 (0.00%)

2 (2.50%)

0.520

  1. Kruskal-Wallis test. Chi-Square test. *p < 0.05, **p < 0.01
  2. Continuous data were expressed as median and IQR
  3. Categorical data were expressed as number and percentage
  4. CVA Cerebral vascular disease, CRI Chronic renal insufficiency, COPD Chronic obstructive pulmonary disease, CAD Coronary artery disease, ERBD Endoscopic retrograde biliary drainage, ERPD Endoscopic retrograde pancreatic drainage, EPBD Endoscopic papilla balloon dilatation, PT Prothrombin Time, APTT Activated Partial Thromboplastin Time, AST Aspartate transaminase, ALT Alanine transaminase, PAD Periampullary diverticulum